louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02546089: ABI v Dry Needling for Plantar Fasciitis
Official title: Investigating the Effects of Ultrasound Guided Autologous Blood Injection for Chronic Plantar Fasciitis Versus Ultrasound Guided Dry-needling Alone, a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Plantar Fasciitis
Lead sponsor: University Hospitals, Leicester
Sponsor class: OTHER
First posted: 2015-09-10
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate whether a procedure of ultrasound-guided autologous blood injections (ABI), which includes a dry-needling component within the overall procedure, has any measureable clinical benefit over ultrasound-guided dry needling alone in patients with chronic plantar fasciitis.


Eligibility criteria: Inclusion Criteria:

1. Patients aged 18 or over who are being seen in the Department of Sports Medicine (all of whom are age 16 or over) with chronic plantar fasciitis of at least 6 months duration
2. Failure of previous conservative therapy - including physiotherapy, and podiatry input
3. Objective evidence of plantar fasciitis - either ultrasound or MRI investigations
4. No contraindications of injection therapy - anticoagulation, blood borne illness, strong needle phobia ...

Exclusion Criteria:

1. Patients with either partial or full-thickness tears of plantar fascia found on investigations
2. Subjects who are unable to give valid consent for study entry based on normal competency assessment
3. Subjects unable or unwilling to undergo the rehabilitation plan post-procedure
4. Subjects unable or unwilling to attend the follow-up appointments post-procedure

Primary outcomes:
measure: Reduction in pain - as assessed by 0-10 VAS scale
timeFrame: 3 & 6 months - primary outcome set at 6 months for study, but using 3 month interim result as well
Secondary outcomes:
measure: Reduction in pain / improvement in function - as assessed by several PROMS (as below)
timeFrame: 3 & 6 months
Other outcomes:
Locations:
city: Leicester
country: United Kingdom
facility: University Hospitals of Leicester NHS Trust
Study officials:
affiliation: UHL NHS Trust
name: Patrick Wheeler
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04484389: Telerehabilitation in Individuals With Chronic Disease
Official title: Effects of Exercise With Telerehabilitation on Depression, Quality of Life and Fatigue in Individuals With Chronic Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Telerehabilitation
Keywords: Chronic Disease
Exercises
Social Isolation
Lead sponsor: Istinye University
Sponsor class: OTHER
First posted: 2020-07-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Telerehabilitation applications are a treatment method that uses new technologies. There are examples of doing for many diseases in our country. It is a method used for people living in remote areas and people who cannot complete their treatment in hospitals due to the epidemic. In our study, we will use the telerehabilitation system. In this system, which we will use in people with chronic disease, we aim to see improvement in tests performed in many areas such as physical activity level, respiratory capacity, depression, and anxiety level of patients.

In the study to be performed on 60 patients, 30 people will be control and 30 people will be the experimental group. The experimental group will be treated with a video conferencing method, tailor-made exercise program based on the international physical activity questionnaire level for 30 minutes 3 days a week for 6 weeks. The control group will only be informed with the help of a brochure with a standard exercise program.

The tests we can use in this experiment are as follows: Barthel daily life activities index, beck depression and anxiety scale, ferrans power quality of life index, Charlson comorbidity index, environmental measurements, waist/hip ratio, fatigue severity scale, international physical activity questionnaire. Tests specific to chronic diseases will be applied to patient one to one.


Eligibility criteria: Inclusion Criteria:

* Having a chronic disease
* To be able to communicate verbally
* Being in a stable period in terms of disease
* At least 3 months for the disease to be chronic
* Regulated hypertension
* Diabetes patients should have them blood sugar under 200 during therapy

Exclusion Criteria:

* Dementia
* Being a cancer patient receiving chemotherapy
* Epilepsy and a history of seizures
* Patient who has recently undergone surgery
* Pregnancy
* Delirium
* Bedridden

Primary outcomes:
measure: Beck Depression Inventory
timeFrame: 2 weeks
Secondary outcomes:
measure: Charlson Comorbidity Index
timeFrame: 2 weeks
Other outcomes:
measure: The Beck Anxiety Inventory
timeFrame: 2 weeks
measure: MODIFIED FATIGUE IMPACT SCALE
timeFrame: 2 weeks
measure: The Fatigue Severity Scale
timeFrame: 2 weeks
measure: Ferrans and Powers quality of life index
timeFrame: 2 weeks
measure: Chest Circumference Measurement
timeFrame: 2 weeks
measure: Waist to Hip Ratio
timeFrame: 2 weeks
measure: INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE
timeFrame: 2 weeks
Locations:
Study officials:
References:
Clinical trial NCT05374889: Evaluation of the Contribution of Basketball-specific Target Shooting Exercises to Strength, Position Sense, Stability and Endurance in Young Basketball Players
Official title: The Effect of Open Kinetic Chain Proprioception Exercises on Joint Position Sense, Stability, Endurance and Strength in Adolescent Basketball Players
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Open Kinetic Chain Proprioception Exercises
Keywords: Proprioception
strength
stability
endurance
adolescent basketball player
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2022-05-16
Enrollment: 22
Sex: MALE
Minimum age (years): 13
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to examine the effects of open kinetic chain proprioception exercises on joint position sense, strength, functional stability and endurance in adolescent basketball players

Detailed description: Adolescent basketball players, aged 13-16, were randomly divided into two groups as exercise group (n = 11) and control group (n = 11). Exercise group performed open kinetic chain functional proprioception exercises twice a week for 6 weeks. Control group did not participate in any exercise program. Before and after the exercise program all athletes were subjected to the proprioception test and isokinetic muscle strength test on the isokinetic dynamometer, closed kinetic chain upper extremity stability test and modified push-up test.

Eligibility criteria: Inclusion Criteria:

* being 13-16 years old
* being male
* playing basketball regularly

Exclusion Criteria:

* having any upper extremity muscle injury in the last 6 months,
* having a limitation in the shoulder girdle range of motion,
* having a shoulder, elbow, wrist dislocation problems

Primary outcomes:
measure: Proprioception test- Cybex-Humac NORM
timeFrame: 20 minutes
measure: Peak Torque & Peak Torque/Body Weight- Cybex-Humac NORM
timeFrame: 20 minutes
measure: Closed kinetic chain upper extremity stability test
timeFrame: 5 minutes
measure: Modified push-up test
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Faculty of Medicine, Sports Medicine Department
Study officials:
affiliation: Istanbul University
name: Gulsum Mandir Comert, M.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01591889: Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
Official title: A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Trichomoniasis
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2012-05-04
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Roxane Laboratories' Tinidazole 500 mg Tablet under fed conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to tinidazole or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: 8 days
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Novum Pharmaceutical Research Services
state: Texas
Study officials:
affiliation: Novum Pharmaceutical Research Services
name: Soran Hong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02266589: Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
Official title: Research of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Septic Shock
Sepsis
Keywords: coagulopathy
hydrocortisone
organ failure
hemodynamic improvement induced by hydrocortisone
Lead sponsor: Nanjing PLA General Hospital
Sponsor class: OTHER
First posted: 2014-10-17
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out whether stress doses of hydrocortisone attenuate coagulation dysfunction in patients with septic shock. And discuss the probable mechanism by which little doses of hydrocortisone influence coagulation system in sepsis.

Detailed description: Patients were randomized to receive either low-dose hydrocortisone or matching placebo.Severity of coagulopathy was estimated using ISTH DIC score. We determined the complications and mortality in two groups, and analyzed the relationship between hydrocortisone and coagulopathy.

Eligibility criteria: Inclusion Criteria:

* All patients(age≧18y)
* Admitted for septic shock were considered eligible if they had no life-threatening systemic disease (ASA groups 1\~3)

Exclusion Criteria:

* Lactation
* Mental disorders
* Disseminated cancer
* Secondary cancers
* Inflammatory bowel disease, or diseases hindering epidural analgesia

Primary outcomes:
measure: coagulopathy
timeFrame: 30 days after inclusion
Secondary outcomes:
measure: death
timeFrame: 30 days after inclusion
measure: clinical complications
timeFrame: 30 days after inclusion
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02730689: A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone
Official title: A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: DP-R207
Rosuvastatin
Ezetimibe
Lead sponsor: Alvogen Korea
Sponsor class: INDUSTRY
First posted: 2016-04-06
Enrollment: 66
Sex: MALE
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to compare the pharmacokinetics of DP-R207 (Rosuvastatin 10mg and Ezetimibe 10mg fixed dose combinations) in comparison to each component administered alone in health male volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects age between 19 and 55 signed informed consent

Exclusion Criteria:

* subjects have an allergy reaction of this drug

Primary outcomes:
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 0-72hr
measure: Peak Plasma Concentration (Cmax)
timeFrame: 0-72hr
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06005389: Serum Galectin-3 as a Marker of Human Papillomavirus Infection
Official title: Serum Galectin-3: A Potential Marker of Human Papillomavirus Infection Before and After Treatment of Cutaneous Warts
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Human Papillomavirus Infection
Keywords: Galectin-3
Human papillomavirus
Warts
Cryotherapy
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-08-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This case-control study was performed on 50 patients with any type of cutaneous warts except for genital warts and 50 apparently healthy age-and sex-matched control subjects without a history of warts attending the Outpatient Clinic of Dermatology, Venereology and Andrology Department of Assiut University Hospitals.

Brief summary: This study aimed to assess the serum Galectin-3 levels in patients with warts both before and after cryotherapy and to investigate its potential contribution to the pathogenesis of human papillomavirus infection.

Detailed description: Galectin-3 regulates many functions at the cellular level such as cell attachment, proliferation, and apoptosis. Numerous viral illnesses, including human papillomavirus infection, were reported to have elevated serum levels of Galectin-3. .

Methods: Fifty patients suffering from warts, and fifty healthy controls were included in this study. Enzyme-linked immunosorbent assay was used to measure serum levels of Galectin-3 both before and 2 weeks after the last cryotherapy session.

Eligibility criteria: Inclusion criteria:

1. Patients with non-genital warts.
2. Age of patients: from 18 to 60 years.

Exclusion criteria:

1. Patients with genital and mucosal warts.
2. Pregnancy and breastfeeding.
3. Patients who received any wart treatment during the last month before enrollment in the study.

Primary outcomes:
measure: Serum Galectin-3 levels assessment in patients with cutaneous warts.
timeFrame: 1 year
measure: look at Galectin-3 serum level conceivable contribution to the aetiology of HPV infection, and determine how cryotherapy affected serum Galectin-3 levels.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References:
citation: Coppock JD, Mills AM, Stelow EB. Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases. Head Neck Pathol. 2021 Mar;15(1):163-168. doi: 10.1007/s12105-020-01195-3. Epub 2020 Jun 20.
Clinical trial NCT02913989: Characterization of Smoking Habits Patterns in Medical Doctors of a Central Hospital in Portugal - What Has Changed After 15 Years? A Comparative Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking Cessation; Tobacco Dependence
Lead sponsor: Centro Hospitalar Lisboa Ocidental
Sponsor class: OTHER_GOV
First posted: 2016-09-26
Enrollment: 423
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All medical doctors working in the central hospital studied between 1/1/2014 and 30/6/2014

Brief summary: Abstract: Tobacco dependence remains one of the primary health care concerns worldwide. Attitude of healthcare professionals towards smoking is crucial for any long-term prevention and smoking cessation program.

Objectives: Analyze smoking habits of medical doctors from a central hospital in Lisbon (2014), comparing results between medical versus surgical specialities. Results were compared with those obtained in 1999.

Design and setting: A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.

Participants: All medical doctors working in the central hospital studied between 1/1/2014 and 30/6/2014 Outcome measures: The primary outcome measure was to characterize the smoking habits of medical doctors. Secondary outcomes included comparison of results between surgical and medical groups and with those obtain in a similar study in 1999.


Eligibility criteria: Inclusion Criteria:

* All medical doctors working in the central hospital studied between 1/1/2014 and 30/6/2014

Exclusion Criteria:

* Not a medical doctor

Primary outcomes:
measure: Analyze smoking habits of medical doctors from a central hospital in Lisbon (2014), comparing results between medical versus surgical specialities.
timeFrame: 1 March 2014 - 30 June 2014
Secondary outcomes:
measure: Comparison of smoking habits of medical doctors in 2014 with a similar study in 1999 in the same hospital.
timeFrame: 1999 and 2014 - 15 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01759589: Three Anaesthesic Method in Electroconvulsive Theraphy
Official title: Sevoflurane Alone and Propofol With or Without Remifentanil in Electroconvulsive Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anesthesia
Keywords: electroconvulsive therapy,sevoflurane,propofol,remifentanil
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2013-01-03
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To compare the effectiveness of three different anesthetic regimens (propofol, remifentanil-propofol and sevoflurane in ECT.

Detailed description: The purpose of this study is to compare the effectiveness of three different anesthetic regimens (propofol, remifentanil-propofol and sevoflurane) with respect to seizure duration, postictal suppression index, early and midictal amplitude, hemodynamic variables and recovery profiles in ECT.

Eligibility criteria: Inclusion Criteria:

* Upremedicated ASA I-II (American Society of Anesthesiologists's physical status) patients,
* Patients scheduled for six ECT sessions for a variety of psychiatric conditions (major depression, schizophrenia)

Exclusion Criteria:

* Involuntary patient status
* Patients with known or self-declared needle or mask phobia
* Pregnancy
* Asthma
* Cerebrovascular disease,
* History of myocardial infarction in the previous 6 months,
* Atrial fibrillation or flutter,heart block,
* A known or family history of reactions to the study drugs.

Primary outcomes:
measure: Seizure duration
timeFrame: The patients were observed about seizure up to ten minutes after electrical stimulation
Secondary outcomes:
measure: postictal suppression index
timeFrame: completing seizure in one hour
measure: Recovery parameters (spontaneous breathing, eye opening, and obeying of verbal commands)
timeFrame: after seizure in one hour in operation room.
measure: Hemodynamic variables
timeFrame: Before administration of the study medications (t0), and at 1 (t1), 3 (t2), and 10 (t3) minutes after the seizure ended.
Other outcomes:
Locations:
city: Malatya
country: Turkey
facility: Turgut Ozal Medical Center
Study officials:
name: Zekine Begec
role: STUDY_DIRECTOR
References:
citation: Toprak HI, Gedik E, Begec Z, Ozturk E, Kaya B, Ersoy MO. Sevoflurane as an alternative anaesthetic for electroconvulsive therapy. J ECT. 2005 Jun;21(2):108-10. doi: 10.1097/01.yct.0000166633.73555.28.
Clinical trial NCT00797589: Effect of Prime Solution on Fluid Balance After Open Heart Surgery
Official title: Effect of Prime Solution on Fluid Balance After Open Heart Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Valve Surgery
Coronary Artery Bypass Grafting
Keywords: aorta valve
mitral valve
coronary artery bypass grafting surgery
perfusion
priming
Lead sponsor: University of Helsinki
Sponsor class: OTHER
Collaborators: name: B. Braun Melsungen AG
First posted: 2008-11-25
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The use of Tetraspan® as prime solution can reduce fluid extravasation after perfusion versus Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.

Detailed description: Fifty patients scheduled for elective primary and single cardiac surgery include in this prospective study. Patients with preoperative coagulation disorders, or renal or hepatic failure, are excluded.

Before admission to the operation theatre, the patients allocate in random order to receive one of the following solutions during the extracorporeal circulation:

1. Ringer-acetate solution
2. 6% HES solution (Tetraspan®) During the 1 postoperative day we register hemodynamic changes, fluid balance, fluid extravasation, plasma ion concentration, modified thromboelastography, and kidney function.

Eligibility criteria: Inclusion Criteria:

* Elective combined cardiac surgery

Exclusion Criteria:

* Liver failure
* Kidney failure

Primary outcomes:
measure: fluid balance
timeFrame: 1 postoperative day
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital
Study officials:
affiliation: Helsinki University Central Hospital
name: Raili T Suojaranta-Ylinen, MD, PhD
role: STUDY_CHAIR
References: